A Study of CAN008 for Newly Diagnosed Glioblastoma Multiforme

Inclusion Criteria: * Newly diagnosed and histologically confirmed glioblastoma multiforme * Tumor must be surgically accessible and tissue must be available * Age ≥ 20 years and \< 75 years * Life expectancy ≥ 6 months * Baseline MRI images must be done within 2 days after surgery * Patients must have a Karnofsky performances score ≥ 60 prior to treatment. * Patients must not have received prior cytotoxic drug therapy, non-cytotoxic drug therapy, or experimental drug therapy for brain tumors. * Adequate hematologic (absolute neutrophil count (ANC) ≥ 1.5x109/L, platelet count ≥ 100x109/L, hemoglobin ≥ 10 g/dL ), renal (creatinine ≤ 1.25xULN ), and hepatic function (total bilirubin ≤ 1.5xULN, aspartate aminotransferase (AST) and alanine aminotransferase (ALT) ≤ 2.5xULN) * Women with childbearing potential must have a negative serum pregnancy test less than 7 days prior to the first dose of study drug. * Both men and women of reproductive potential agree to use approved contraception, such as condom and placement of an intrauterine device (IUD), during the study and until 3 months after the discontinuation of study treatment. * Willing and able to comply with the protocol as judged by the investigator * Patients must provide written consent Exclusion Criteria: * Any prior chemotherapy (including carmustine-containing wafers) or immunotherapy (including vaccine therapy ) * Any prior radiotherapy to the brain * Any concurrent malignancy other than basal cell carcinoma or carcinoma in situ of the cervix. Patients with a previous malignancy but without evidence of disease for ≥ 5 years will be allowed to enter the trial * Any contraindication to TMZ listed in the local label * Low-grade astrocytoma * Unable to undergo MRI * Past medical history of disease with poor prognosis according to the judgment of the Investigator * HIV infection * Patients with positive anti-HCV * Patients with positive HbsAG who received any related treatment within the past 6 months * Patients suffering from hereditary fructose intolerance (HFI). * Patients receive any investigational agent(s) or device(s) within 30 days prior to entering the study * Known coronary artery disease, significant arrhythmias or severe congestive heart failure